Last Update Time:
13-Mar-2025 16:00:00
ISIN:
INE351Y01019
Sector:
Healthcare
Symbol:
BETA
Beta Drugs Limited
₹1,731.00
₹68.30
(4.11%)
▲
Prev. Close
₹1,662.70
Open
₹1,665.05
Close
₹1,706.40
Range
₹1,644.45 - ₹1,817.55
High
₹1,731.00
Low
₹1,650.00
Ind. Close
₹0.00
VWAP
₹1,679.60
The current stock price of Beta Drugs Limited is ₹1,731.00, with a target price range between ₹1,644.45 and ₹1,817.55. The stock has experienced a price change of ₹68.30 (4.11%), reflecting recent market volatility.
Today's opening price was ₹1,665.05, while the previous close stood at ₹1,662.70.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Beta Drugs Limited Price Chart
Beta Drugs Limited Pre Open Market Overview: 13-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 0
- Previous Close Price: 1662.7
- Change: -1,662.70%
- Total Traded Volume: 0
- Total Buy Quantity: 500
- Total Sell Quantity: 400
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 0.00 | 0.00 | 0.00 |
| 1,495.00 | 100.00 | 0.00 |
| 1,581.00 | 100.00 | 0.00 |
| 1,601.00 | 100.00 | 0.00 |
| 1,602.00 | 100.00 | 0.00 |
| 1,719.80 | 0.00 | 100.00 |
| 1,719.90 | 0.00 | 100.00 |
| 1,790.00 | 0.00 | 100.00 |
| 1,850.00 | 0.00 | 100.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 500
Total Sell Quantity: 400
Shareholding Patterns of Beta Drugs Limited
Key Trade Statistics of Beta Drugs Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.03 |
| Traded Value (₹ Cr.) | 0.50 |
| Total Market Cap (₹ Cr.) | 1,664.16 |
| Free Float Market Cap (₹ Cr.) | 342.81 |
| Impact cost | N/A |
| Quantity Traded | 3,000.00 |
| Deliverable Quantity | 2,600.00 |
| % of Quantity to Traded | 86.67 |
| Security VaR | N/A |
| Index VaR | N/A |
| VaR Margin | 50 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 53.5 |
| Face Value | 10 |
Key Price Statistics of Beta Drugs Limited
The 52-week high for Beta Drugs Limited was ₹2,326.00, recorded on 11-Nov-2024. On the other hand, the 52-week low stands at ₹1,060.05, with the lowest value recorded on 13-Mar-2024.
The upper band for trading is ₹1,995.20, and the lower band is ₹1,330.20. The price band is 20%.
The stock's daily volatility stands at N/A, while the annualized volatility is N/A. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (11-Nov-2024) | 2,326.00 |
| 52 Week Low (13-Mar-2024) | 1,060.05 |
| Upper Band | 1,995.20 |
| Lower Band | 1,330.20 |
| Price Band (%) | 20 |
| Daily Volatility | - |
| Annualised Volatility | - |
| Tick Size | 0.05 |
Key Securities Statistics of Beta Drugs Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 12-Oct-2017 |
| Adjusted P/E | 40.01 |
| Symbol P/E | 40.01 |
| Index | NIFTY SME EMERGE |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Beta Drugs Limited
| Title | Details |
|---|---|
| Board Status | SME |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Beta Drugs Limited
| Subject | Date |
|---|---|
| Shareholders meeting | 12-Mar-2025 |
| General Updates | 12-Mar-2025 |
| Amendment to AOA/MOA | 12-Mar-2025 |
| Shareholders meeting | 12-Mar-2025 |
| Copy of Newspaper Publication | 07-Feb-2025 |
| Notice Of Shareholders Meetings-XBRL | 06-Feb-2025 |
| Shareholders meeting | 06-Feb-2025 |
| General Updates | 06-Feb-2025 |
Corporate Actions of Beta Drugs Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 10 | ANNUAL GENERAL MEETING | 23-Sep-2024 |
| 10 | ANNUAL GENERAL MEETING | 22-Sep-2023 |
| 10 | ANNUAL GENERAL MEETING | 20-Sep-2022 |
| 10 | ANNUAL GENERAL MEETING | 21-Sep-2021 |
| 10 | ANNUAL GENERAL MEETING | 21-Sep-2020 |
| 10 | ANNUAL GENERAL MEETING | 19-Sep-2019 |
| 10 | ANNUAL GENERAL MEETING | 18-Sep-2018 |
Board Meetings of Beta Drugs Limited
Financial Results of Beta Drugs Limited
Company Directory of Beta Drugs Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.betadrugslimited.com | Registered Address | Village Nandpur Baddi, Himachal Pradesh-17410 BADDI - 174101 SOLAN | BADDI |
Insider Trading of Beta Drugs Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Rahul Batra | 1644580 | Buy |
| 7(2) | Rahul Batra | 1644580 | Buy |
| 7(2) | Rahul Batra | 1674740 | Buy |
| 7(2) | Vijay Kumar Batra | 826616 | Buy |
| 7(2) | Vijay Kumar Batra | 4281480 | Buy |
| 7(2) | Vijay Kumar Batra | 941320 | Buy |
| 7(2) | Vijay Kumar Batra | 2071960 | Buy |
| 7(2) | Vijay Kumar Batra | 998376 | Buy |
| 7(2) | Neeraj Batra | 2149650 | Buy |
| 7(2) | Varun Batra | 1663200 | Buy |
| 7(2) | Rahul Batra | 1773000 | Buy |
| 7(2) | Vijay Kumar Batra | 16528320 | Buy |
| 7(2) | Vijay Kumar Batra | 2547072 | Buy |
| 7(2) | Vijay Kumar Batra | 35.99 | Buy |
Annual Reports of Beta Drugs Limited
Investor Complaints of Beta Drugs Limited
Event Calendar of Beta Drugs Limited
| Purpose | Details |
|---|---|
| Board Meeting Intimation | BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 05-Feb-2025 to consider and approve Bonus/Other business. |
| Bonus/Other business matters | To consider bonus and other business matters including Migration of listing / trading of equity shares of the company from Emerge platform of National Stock Exchange of India Limited (NSE) to main board of National Stock Exchange of India Limited as well as on main board of BSE Ltd. |
| Board Meeting Intimation | BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 27-Nov-2024 to consider Other business. |
| Other business matters | To consider other business matters 1. To consider & approve the allotment of 100 fully paid-up equity shares of the Company of face value of Rs. 10 each, at a price of Rs 1,653.40 per Equity Share including a premium of Rs. 1,643.40 per Equity Share and 7,07,651 fully paid up unsecured compulsory convertible debentures of the Company ( CCDs ) of face value of Rs. 1,653.40 each under Preferential Issue, pursuant to approval obtained from shareholders in Extra Ordinary General Meeting held on 12th November, 2024.2. To consider, approve & adopt the restated Article of Association of the company, subject to the approval of shareholders of the company in their meeting. |
| Board Meeting Intimation | BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2024 . |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 19-Oct-2024 to consider Fund raising. | Board Meeting Intimation |
| Fund Raising | To consider Fund Raising |
| BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 14-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2024 . | Board Meeting Intimation |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2024 |
| Financial Results/Other business matters | 1.To consider and approve the financial results for the period ended September 30, 2023 .2. To consider the Migration of the Equity shares of the Company from Emerge-SME Platform of National Stock Exchange of India Limited ( NSE Emerge ) to the Main board of National Stock Exchange of India Limited & Bombay Stock Exchange of India Limited. |
| BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 07-Nov-2023 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2023 and Other business. | Board Meeting Intimation |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2023. 2. To consider the Migration of the Equity shares of the Company from Emerge-SME Platform of National Stock Exchange of India Limited ( NSE Emerge ) to the Main board of National Stock Exchange of India Limited & Bombay Stock Exchange of India Limited. |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2023 |
| Financial results | Beta Drugs Limited has informed the Exchange about Board Meeting to be held on 27-Oct-2022 to consider financial statements for the period ended September 2022 |
| Financial results | Beta Drugs Limited has informed the Exchange about Board Meeting to be held on 27-Apr-2022 to consider financial statements for the period ended March 2022 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Other business matters | To consider other business matters |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
Share Transfers of Beta Drugs Limited
Voting Results of Beta Drugs Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 11-MAR-2025 | Postal Ballot | TO APPROVE THE INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY AND CONSEQUENT ALTERATION IN THE CAPITAL CLAUSE OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY. |
| 11-MAR-2025 | Postal Ballot | MIGRATION OF LISTING / TRADING OF EQUITY SHARES OF THE COMPANY FROM EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED TO MAIN BOARD OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (￢ﾀﾜNSE￢ﾀﾝ) AS WELL AS ON MAIN BOARD OF BSE LIMITED (￢ﾀﾜBSE￢ﾀﾝ): |
| 11-MAR-2025 | Postal Ballot | APPOINTMENT OF MR LALIT KUMAR WATTS (DIN:10906518) AS AN INDEPENDENT DIRECTOR OF THE COMPANY |
| 11-MAR-2025 | Postal Ballot | APPOINTMENT OF MRS MONICA JAIN (DIN: 05253864) AS AN INDEPENDENT DIRECTOR OF THE COMPANY |
| 11-MAR-2025 | Postal Ballot | ISSUE OF BONUS SHARES |
| 21-DEC-2024 | EGM | ADOPTION OF THE RESTATED ARTICLES OF ASSOCIATION OF THE COMPANY. |
| 21-DEC-2024 | EGM | APPOINTMENT OF MR. AJAY MAHIPAL (DIN: 06949940) AS A DIRECTOR OF THE COMPANY. |
| 21-DEC-2024 | EGM | APPOINTMENT OF MR. SANJAY SEHGAL, (DIN: 01235531) AS INDEPENDENT DIRECTOR OF THE COMPANY. |
| 12-NOV-2024 | EGM | 1. TO APPROVE THE INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY AND CONSEQUENT ALTERATION IN THE CAPITAL CLAUSE OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY. nn |
| 12-NOV-2024 | EGM | APPROVAL OF SPECIAL RIGHTS PROPOSED TO BE GRANTED TO HEALTHQUAD FUND II (A FUND UNDER HEALTHQUAD TRUST II) AND Inti Capital VCC - Inti Capital I |
| 12-NOV-2024 | EGM | ISSUANCE OF EQUITY SHARES AND COMPULSORY CONVERTIBLE DEBENTURES OF THE COMPANY ON PREFERENTIAL BASIS |
| 30-SEP-2024 | AGM | 1. Adoption of Financial Statementsnn(I) Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2024 and the Reports of the Board of Directors and Auditors thereon;n andn (II) Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2024, together with the Report of the Auditors thereonn |
| 30-SEP-2024 | AGM | Re-appointment of Mrs. Seema Chopra (DIN: 08510586) as Whole-time Director of the Company w.e.f. 1st August, 2024 till 31st July, 2029. |
| 30-SEP-2024 | AGM | Re-appointment of Mr. Balwant Singh (DIN: 01089968) as Whole-time Director of the Company w.e.f. 5th August, 2024 till 4th August, 2029. |
| 30-SEP-2024 | AGM | To revise the remuneration payable to Mr. Varun Batra (DIN No. 02148383), Joint Managing Director of the company. |
| 30-SEP-2024 | AGM | To revise the remuneration payable to Mr. Rahul Batra (DIN No. 02229234), Managing Director of the company. |
| 30-SEP-2024 | AGM | To ratify the remuneration payable to the Cost Auditor appointed by the Board of Directors of the Company for the financial year 2024-25 pursuant to Section 148 and all other applicable provisions of Companies Act, 2013. |
| 30-SEP-2024 | AGM | To appoint Statutory Auditors from the conclusion of this Annual General Meeting until the conclusion of the Twenty first Annual General Meeting and to fix their remuneration. |
| 30-SEP-2024 | AGM | To appoint a Director in place of Mrs. Seema Chopra (DIN: 08510586), who retires by rotation and being eligible, offers herself for re-appointment. |
| 30-SEP-2024 | AGM | To appoint a Director in place of Mr. Varun Batra (DIN: 02148383), who retires by rotation and being eligible, offers himself for re-appointment. |
FAQs on Beta Drugs Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.